Zacks: Analysts Anticipate BIONDVAX PHARMA/S (NASDAQ:BVXV) Will Post Earnings of -$0.03 Per Share
Equities research analysts expect BIONDVAX PHARMA/S (NASDAQ:BVXV) to report earnings of ($0.03) per share for the current quarter, Zacks reports. Zero analysts have made estimates for BIONDVAX PHARMA/S’s earnings. BIONDVAX PHARMA/S posted earnings per share of ($0.11) during the same quarter last year, which suggests a positive year-over-year growth rate of 72.7%. The company is scheduled to announce its next earnings results on Tuesday, November 12th.
On average, analysts expect that BIONDVAX PHARMA/S will report full year earnings of ($0.08) per share for the current year. For the next year, analysts forecast that the firm will post earnings of ($0.07) per share. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side analysts that that provide coverage for BIONDVAX PHARMA/S.
Separately, ValuEngine raised BIONDVAX PHARMA/S from a “hold” rating to a “buy” rating in a research note on Thursday, September 5th.
About BIONDVAX PHARMA/S
BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. Its product candidate is M-001, a synthetic peptide-based protein, which has completed Phase II clinical trials that is used for treating seasonal and pandemic strains of the influenza virus.
Read More: What is a Derivative?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BIONDVAX PHARMA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIONDVAX PHARMA/S and related companies with MarketBeat.com's FREE daily email newsletter.